Market Research Logo

Global Migraine Market Report: 2016 Edition

Global Migraine Market Report: 2016 Edition

Migraine is a common neurovascular disorder that is characterized by throbbing headaches and is commonly associated with other neurological symptoms, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraines are thought to result from the activation and sensitization of sensory neurons that have nerve endings in meningeal blood vessels. Migraines can be episodic or chronic. Chronic Migraine (CM) and Episodic Migraine (EM) are both part of the spectrum of migraine disorders, but are distinct clinical entities. The onset of migraine is preceded by certain triggers, which can be unique for each migraine sufferer.

Triptans and Ergots are among the most common drug options existing in the treatment market for migraine. The global migraine treatment market currently faces several unmet needs and is saturated with the availability of generic drugs. Several branded drugs are under development with safer and more effective profiles, given the vast opportunities existing in the market. The focus of upcoming drugs is to either cure migraine or to reduce the frequency to a level where patients can find tolerable relief.

The migraine market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing female population and rising awareness among physicians and patients. The major growth drivers of the migraine market includes rising spending on medicines, growing female population, increasing cigarette consumption and healthcare expenditure. However, the growth of the market will also remain challenged by complications associated with Triptans, treatment limitations for patients with CV (Cardio Vascular) risk and increased preference for OTC (Over the Counter) medications.

The report, “Global Migraine Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific market of the U.S. is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.


1. Market Overview
1.1 Introduction
1.2 Types
1.3 Causes and Pathogenesis
Table A: Common Migraine Triggers
1.4 Symptoms and Diagnosis
1.5 Treatment Options
Table B: Current Treatment Options for Moderate to Severe Episodic Migraine
2. Global Migraine Market
2.1 Global Migraine Drug Market by Value
Table 1: Global Migraine Drug Market by Value (2013-2020E)
2.2 Global Migraine Drug Market by Category
Table 2: Global Migraine Drug Market by Category (2015E)
2.3 Global Therapeutic Botulinum Toxin Market by Value
Table 3: Global Therapeutic Botulinum Toxin Market (2013-2020E)
2.4 Global Therapeutic Botulinum Toxin Market by Indication
Table 4: Global Therapeutic Botulinum Toxin Market by Indication (2015)
3. The U.S. Migraine Market
3.1 The U.S. Total Migraine Population
Table 5: The U.S. Total Migraine Population (2015-2022E)
3.2 The U.S. Migraine Population by Diagnosis
Table 6: The U.S. Migraine Population by Diagnosis (2015E)
3.3 The U.S. Migraine Population with CV Risk Factors
Table 7: The U.S. Migraine Population with CV Risk Factors (2015-2022E)
3.4 The U.S Preventive Migraine Treatment by Specialty
Table 8: The U.S. Preventive Migraine Treatment by Specialty (2015)
3.5 The U.S. Acute Migraine Treated Population by Drug Type
Table 9: The U.S. Acute Migraine Treated Population by Drug Type (2014)
3.6 The U.S. Acute Migraine Prescription Volume
Table 10: The U.S. Acute Migraine Prescription Volume (2015-2025E)
3.7 The U.S. Migraine Drugs Revenue
3.7.1 Cambia
Table 11: The U.S. Cambia Drug Revenue (2015-2022E)
3.7.2 Lasmiditan
Table 12: The U.S. Lasmiditan Drug Revenue & Treated Patient (2015-2022E)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Spending on Medicines
Table 13: Global Spending on Medicines (2010-2020E)
Table 14: Pharmaceutical Spending Per Capita by Country (2015)
4.1.2 Growing Female Population
Table 15: Global Female Population (2010-2015)
4.1.3 Increasing Cigarette Consumption
Table 16: Global Cigarette Consumption (1910-2014)
4.1.4 Rising Healthcare Expenditure
Table 17: Global Healthcare Expenditure (2010-2015E)
4.2 Trends
4.2.1 Emergence of Peripheral Nerve Stimulators
Table 18: Global FDA Neuromodulator Trials by Category (2014)
4.2.2 Increased Preference for Non Pharmacological Treatment
Table 19: Reasons for Initiation of VNS Therapy among Patients (2015)
Table 20: Reasons for Continuation of VNS Therapy among Patients (2015)
4.2.3 Higher Prevalence of Migraine than Other Chronic Diseases
Table 21: Percentage of People Affected in the U.S. (2014)
4.2.4 Recurrent Symptoms in Migraine Patients
Table 22: Common Symptoms in Migraine Patients (2015)
4.2.5 Drugs under Development for Migraine
Table C: Non-Triptans Migraine Drugs under Development
4.3 Challenges
4.3.1 Complications associated with Triptans
4.3.2 Treatment Limitations for Patients with Cardiovascular Disease
4.3.3 Rise in Prescription Drugs to OTC Switch
Table 23: Global Over the Counter (OTC) Drug Market (2010-2014)
5. Competitive Landscape
Table D: Global Migraine Competitors Comparison (2015)
6. Company Profiles
6.1 Amgen Inc.
6.1.1 Business Overview
Table 24: Amgen Inc. Revenue Share by Geography (2015)
6.1.2 Financial Overview
Table 25: Amgen Inc. Revenue and Net Income (2011-2015)
6.1.3 Business Strategies
Table 26: Amgen Inc. Research and Development Expenditure (2011-2015)
6.2 Teva Pharmaceuticals
6.2.1 Business Overview
Table 27: Teva Pharmaceuticals Product Sales by Segment (2015)
6.2.2 Financial Overview
Table 28: Teva Pharmaceuticals Revenue and Net Income (2011-2015)
6.2.3 Business Strategies
Table 29: Teva Pharmaceuticals Research & Development Expenditure (2011-2015)
6.3 Eli Lilly and Company
6.3.1 Business Overview
Table 30: Eli Lilly Revenue by Segments (2015)
6.3.2 Financial Overview
Table 31: Revenue and Net Income of Eli Lilly and Company (2011-2015)
6.3.3 Business Strategies
Table 32: Research and Development Expenditure of Eli Lilly (2011-2015)
Table E: Product and Other Acquisitions of Eli Lilly
6.4 AstraZeneca
6.4.1 Business Overview
Table 33: AstraZeneca Revenue by Therapeutic Segment (2015)
6.4.2 Financial Overview
Table 34: AstraZeneca Revenue by Regions (2015)
6.4.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report